SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-085127
Filing Date
2022-03-25
Accepted
2022-03-25 16:03:33
Documents
12
Period of Report
2022-03-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d309668d8k.htm   iXBRL 8-K 22132
  Complete submission text file 0001193125-22-085127.txt   139503

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA gbt-20220324.xsd EX-101.SCH 2831
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE gbt-20220324_lab.xml EX-101.LAB 17237
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gbt-20220324_pre.xml EX-101.PRE 10797
6 EXTRACTED XBRL INSTANCE DOCUMENT d309668d8k_htm.xml XML 3248
Mailing Address 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Business Address 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080 650741-7700
Global Blood Therapeutics, Inc. (Filer) CIK: 0001629137 (see all company filings)

IRS No.: 274825712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37539 | Film No.: 22771338
SIC: 2834 Pharmaceutical Preparations